** Shares in Elekta EKTAb.ST rise 6.9% after the Swedish medical technology company's order book grew more than expected in Q3
** In Jefferies's view Elekta delivered a "reassuring" Q3 report with order intake growing by 3% at constant currencies, despite tough comparisons, above consensus expectations of a +0% growth
** Orders were helped by strong performance in China and the US, as well as European service orders, the company says in its statement
** Jefferies notes that adj. EBIT margin of 11.9%, up 20bp y/y, landed roughly in-line with consensus estimate of 11.7% as it was held back by negative impacts from foreign exchange and tariffs
** "By Elekta's historic standards, this is a relatively in-line set of numbers," J.P.Morgan says, adding that lack of further downside could be seen as a small relief
** The company reiterated its outlook for 2025/2026
** Elekta shares are on track for their best day since November 2025
(Reporting by Agnieszka Olenska)
((Agnieszka.Olenska@thomsonreuters.com;))